Evidence map›Paper›PMID 28694660›Full record

ArticleWorld journal of gastroenterology2017

Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: Effects in an

Chiara Dianzani, Federica Foglietta, Benedetta Ferrara, Arianna Carolina Rosa, Elisabetta Muntoni, Paolo Gasco, Carlo Della Pepa, Roberto Canaparo, Loredana Serpe

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Chiara DianzaniChiara Dianzani, Federica Foglietta, Benedetta Ferrara, Arianna Carolina Rosa, Elisabetta Muntoni, Carlo Della Pepa, Roberto Canaparo, Loredana Serpe, Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy.
Federica FogliettaChiara Dianzani, Federica Foglietta, Benedetta Ferrara, Arianna Carolina Rosa, Elisabetta Muntoni, Carlo Della Pepa, Roberto Canaparo, Loredana Serpe, Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy.
Benedetta FerraraChiara Dianzani, Federica Foglietta, Benedetta Ferrara, Arianna Carolina Rosa, Elisabetta Muntoni, Carlo Della Pepa, Roberto Canaparo, Loredana Serpe, Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy.
Arianna Carolina RosaChiara Dianzani, Federica Foglietta, Benedetta Ferrara, Arianna Carolina Rosa, Elisabetta Muntoni, Carlo Della Pepa, Roberto Canaparo, Loredana Serpe, Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy.
Elisabetta MuntoniChiara Dianzani, Federica Foglietta, Benedetta Ferrara, Arianna Carolina Rosa, Elisabetta Muntoni, Carlo Della Pepa, Roberto Canaparo, Loredana Serpe, Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy.
Paolo GascoChiara Dianzani, Federica Foglietta, Benedetta Ferrara, Arianna Carolina Rosa, Elisabetta Muntoni, Carlo Della Pepa, Roberto Canaparo, Loredana Serpe, Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy.
Carlo Della PepaChiara Dianzani, Federica Foglietta, Benedetta Ferrara, Arianna Carolina Rosa, Elisabetta Muntoni, Carlo Della Pepa, Roberto Canaparo, Loredana Serpe, Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy.
Roberto CanaparoChiara Dianzani, Federica Foglietta, Benedetta Ferrara, Arianna Carolina Rosa, Elisabetta Muntoni, Carlo Della Pepa, Roberto Canaparo, Loredana Serpe, Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy.
Loredana SerpeChiara Dianzani, Federica Foglietta, Benedetta Ferrara, Arianna Carolina Rosa, Elisabetta Muntoni, Carlo Della Pepa, Roberto Canaparo, Loredana Serpe, Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy.
University of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo improve anti-inflammatory activity while reducing drug doses, we developed a nanoformulation carrying dexamethasone and butyrate.

methodsDexamethasone cholesteryl butyrate-solid lipid nanoparticles (DxCb-SLN) were obtained with the warm microemulsion method. The anti-inflammatory activity of this novel nanoformulation has been investigated

resultsDxCb-SLN at the lowest concentration tested (Dx 2.5 nmol/L and Cb 0.1 μmol/L) were able to exert a more than additive effect compared to the sum of the individual effects of each drug, inducing a significant

conclusionOur results indicate that the co-administration of dexamethasone and butyrate by nanoparticles may be beneficial for inflammatory bowel disease treatment.

Indexed as

Drug Delivery SystemsAnimalsAnti-Inflammatory AgentsButyratesCell AdhesionColitisCytokinesDexamethasoneHumansHuman Umbilical Vein Endothelial CellsInflammationInflammatory Bowel DiseasesLeukocytes, MononuclearLipopolysaccharidesMaleMiceAnti-Inflammatory AgentsButyratesCytokinesDexamethasoneLipopolysaccharidesButyrateDexamethasoneDrug delivery systemsInflammatory bowel diseaseNanoparticles

Identifiers

PMID28694660
PMCPMC5483494
OpenAlexW2652176597

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.